Survival benefit of surgical resection after first-line triplet chemotherapy and bevacizumab in patients with initially unresectable metastatic colorectal cancer

Mahmoud A Elshenawy, Ahmed Badran, Ali Aljubran, Ahmed Alzahrani, M Shahzad Rauf, Abdelmoneim Eldali, Shouki Bazarbashi, Mahmoud A Elshenawy, Ahmed Badran, Ali Aljubran, Ahmed Alzahrani, M Shahzad Rauf, Abdelmoneim Eldali, Shouki Bazarbashi

Abstract

Background: Surgical resection of metastatic disease in patients with initially non-resectable colorectal cancer (CRC) has improved overall survival. Intensified chemotherapy regimens have increased the probability of converting unresectable metastasis to resectable. Here, we report the result of combining intensive chemotherapy (triplet) and surgical resection of metastatic lesions in patients with metastatic CRC.

Patients and methods: Patients with unresectable metastatic CRC were enrolled in phase I/II trial of triplet chemotherapy consisting of capecitabine, oxaliplatin, irinotecan, and bevacizumab. Patients were given 5-8 cycles induction chemotherapy of the above regimen followed by maintenance capecitabine and bevacizumab until disease progression, unacceptable toxicity, or patient request. All patients were assessed at a multidisciplinary conference for possible surgical resection of their metastatic disease at the time of inclusion in the trial and 2 monthly intervals thereafter. Patients who underwent R0 resection of their metastatic disease received adjuvant oxaliplatin and capecitabine to complete a total of 6 months of chemotherapy.

Results: Fifty-three patients were enrolled. The median age was 52 years (range 23-74), 29 (55%) were males, ECOG PS 0-1 was 13 (66%), 11 (42%) had a right-sided tumor, 29 (55%) had resection of their primary tumor, 22 (42%) had a single metastatic site, and 8 (15.1%) had a liver-limited disease. Thirteen patients (24.5%) underwent surgical resection of residual metastatic disease +/- the primary tumor with 10 (18.9%) of them were R0. The surgical group had a higher incidence of males compared to the non-surgical group (69.3% vs 47.2%, p = 0.2), equal performance status, lower median number of metastatic sites (1 vs 2, p = 0.09), higher mutant Kras (53.8% vs 34.2%, p = 0.3), and higher response rate (84.6% vs 56.2%, p = 0.3). With a median follow-up duration of 89 months, the median PFS for the whole group was 16.1 months [95% confidence interval (CI) 9.1-20] and the median OS was 28.2 months (95% CI 22.5-53.3). The median PFS for the surgery group was 18.9 months (95% CI 12.6-not reached) compared to 9.6 months (95% CI 7.0-18.3) for the non-surgical group, log-rank p = 0.0165. The median OS for both groups was not reached (95% CI 53.3-not reached) and 23.2 months (95% CI 17.0-28.4) respectively, log-rank p = 0.0006. Five-year PFS and OS for the surgery group were 46.2% and 67.6% respectively.

Conclusions: Patients with unresectable metastatic CRC and fit for triplet chemotherapy should have the benefit of combining this intensified regimen and surgical resection of their metastatic disease if possible.

Trial registration: Clinicaltrials.gov , NCT01311050 , registered March 6, 2011, retrospectively registered.

Keywords: Colorectal cancer; FOLFOXIRI-Bevacizumab; Surgery; Triplet chemotherapy.

Conflict of interest statement

We have no conflicts of interest to declare.

Figures

Fig. 1
Fig. 1
Progression-free survival (PFS) of the whole group
Fig. 2
Fig. 2
Overall survival (OS) of the whole group
Fig. 3
Fig. 3
Progression-free survival (PFS) of the surgical vs the non-surgical groups
Fig. 4
Fig. 4
Overall survival (OS) of the surgical vs the non-surgical groups

References

    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424. doi: 10.3322/caac.21492.
    1. Segal NH, Saltz LB. Evolving treatment of advanced colon cancer. Annu Rev Med. 2009;60:207–219. doi: 10.1146/annurev.med.60.041807.132435.
    1. De Greef K, Rolfo C, Russo A, Chapelle T, Bronte G, Passiglia F, et al. Multisciplinary management of patients with liver metastasis from colorectal cancer. World J Gastroenterol. 2016;22:7215–7225. doi: 10.3748/wjg.v22.i32.7215.
    1. Venook AP, Niedzwiecki D, Lenz HJ, Innocenti F, Fruth B, Meyerhardt JA, et al. Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer a randomized clinical trial. JAMA - J Am Med Assoc. 2017;317:2392–2401. doi: 10.1001/jama.2017.7105.
    1. Stintzing S, Fischer von weikersthal L, Decker T, Vehling-kaiser U, Jäger E, Heintges T, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306. Ann Oncol. 2012;23:1693–1699. doi: 10.1093/annonc/mdr571.
    1. Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chien CRC, Makhson A, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360:1408–1417. doi: 10.1056/NEJMoa0805019.
    1. Van Cutsem E, Köhne CH, Láng I, Folprecht G, Nowacki MP, Cascinu S, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol. 2011;29:2011–2019. doi: 10.1200/JCO.2010.33.5091.
    1. Cremolini C, Loupakis F, Antoniotti C, Lupi C, Sensi E, Lonardi S, et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol. 2015;16:1306–1315. doi: 10.1016/S1470-2045(15)00122-9.
    1. Falcone A, Ricci S, Brunetti I, Pfanner E, Allegrine G, Barbara C, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: The gruppo oncologico nor. J Clin Oncol. 2007;25:1670–1676. doi: 10.1200/JCO.2006.09.0928.
    1. Adam R, Bridgewater J, Chau I, Alfonso PG, Rivoire M, Lasserre S, et al. Randomised, phase 2 study (OLIVIA) of bevacizumab plus mFOLFOX6 or folfoxiri in patients with initially unresectable colorectal cancer liver metastases. Ann Oncol. 2013;24:iv21. doi: 10.1093/annonc/mdt201.25.
    1. Adam R, Wicherts DA, de Haas RJ, Ciacio O, Lévi F, Paule B, et al. Patients with initially unresectable colorectal liver metastases: is there a possibility of cure? J Clin Oncol. 2009;27:1829–1835. doi: 10.1200/JCO.2008.19.9273.
    1. Mayo SC, Pulitano C, Marques H, Lamelas J, Wolfgang CL, de Saussure W, et al. J Am Coll Surg. 2013;216:707–16 Available from: .
    1. Sugarbaker PH. Cytoreductive surgery plus hyperthermic perioperative chemotherapy for selected patients with peritoneal metastases from colorectal cancer: a new standard of care or an experimental approach? Gastroenterol Res Pract. 2012;2012.
    1. Cashin PH, Mahteme H, Spång N, Syk I, Frödin JE, Torkzad M, et al. Cytoreductive surgery and intraperitoneal chemotherapy versus systemic chemotherapy for colorectal peritoneal metastases: a randomised trial. Eur J Cancer. 2016;53:155–162. doi: 10.1016/j.ejca.2015.09.017.
    1. Lin EK, Hsieh MC, Chen CH, Lu YJ, Wu SY. Outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer with peritoneal metastasis. Med (United States). 2016:95.
    1. Ychou M, Rivoire M, Thezenas S, Quenet F, Delpero J-R, Rebischung C, et al. A randomized phase II trial of three intensified chemotherapy regimens in first-line treatment of colorectal cancer patients with initially unresectable or not optimally resectable liver metastases. The METHEP trial. Ann Surg Oncol. 2013;20:4289–4297. doi: 10.1245/s10434-013-3217-x.
    1. Folprecht G, Gruenberger T, Bechstein WO, Raab H-R, Lordick F, Hartmann JT, et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol. 2010;11:38–47. doi: 10.1016/S1470-2045(09)70330-4.
    1. Cremolini C, Marmorino F, Loupakis F, Masi G, Antoniotti C, Salvatore L, et al. TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group. BMC Cancer. 2017;17:408. doi: 10.1186/s12885-017-3360-z.
    1. Souglakos J, Androulakis N, Syrigos K, Polyzos A, Ziras N, Athanasiadis A, et al. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncolog. Br J Cancer. 2006;94:798–805. doi: 10.1038/sj.bjc.6603011.
    1. Bazarbashi S, Aljubran A, Alzahrani A, Mohieldin A, Soudy H, Shoukri M. Phase I/II trial of capecitabine, oxaliplatin, and irinotecan in combination with bevacizumab in first line treatment of metastatic colorectal cancer. Cancer Med. 2015;4:1505–1513. doi: 10.1002/cam4.497.
    1. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer. 2009;45:228–247. doi: 10.1016/j.ejca.2008.10.026.
    1. Shouki B, Ali AJ, Ahmad AZ, Hussein S, Mohammed S. P-0243 * Deep responders represent a group with excellent survival in patients with metastatic colorectal cancer (MCRC) treated with triplet chemotherapy regimens (TCR) Ann Oncol. 2014;25:ii90. doi: 10.1093/annonc/mdu165.238.
    1. Douillard J-Y, Siena S, Peeters M, Koukakis R, Terwey J-H, Tabernero J. Impact of early tumour shrinkage and resection on outcomes in patients with wild-type RAS metastatic colorectal cancer. Eur J Cancer. 2015;51:1231–1242. doi: 10.1016/j.ejca.2015.03.026.
    1. Ye L-C, Liu T-S, Ren L, Wei Y, Zhu D-X, Zai S-Y, et al. Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases. J Clin Oncol. 2013;31:1931–1938. doi: 10.1200/JCO.2012.44.8308.
    1. Shui L, Wu YS, Lin H, Shui P, Sun Q, Chen X. Triplet chemotherapy (FOLFOXIRI) plus bevacizumab versus doublet chemotherapy (FOLFOX/FOLFIRI) plus bevacizumab in conversion therapy for metastatic colorectal cancer: a meta-analysis. Cell Physiol Biochem. 2018;48:1870–1881. doi: 10.1159/000492508.
    1. Schmoll H-J, Meinert FM, Cygon F, Garlipp B, Junghanss C, Leithäuser M, et al. “CHARTA”: FOLFOX/Bevacizumab vs. FOLFOXIRI/Bevacizumab in advanced colorectal cancer—final results, prognostic and potentially predictive factors from the randomized phase II trial of the AIO. J Clin Oncol. 2017;35:3533. doi: 10.1200/JCO.2017.35.15_suppl.3533.
    1. Hurwitz HI, Tan BR, Reeves JA, Xiong H, Somer B, Lenz H-J, et al. Phase II randomized trial of sequential or concurrent FOLFOXIRI-bevacizumab versus FOLFOX-bevacizumab for metastatic colorectal cancer (STEAM) Oncologist. 2019;24:921–932. doi: 10.1634/theoncologist.2018-0344.
    1. Tomasello G, Petrelli F, Ghidini M, Russo A, Passalacqua R, Barni S. FOLFOXIRI plus bevacizumab as conversion therapy for patients with initially unresectable metastatic colorectal cancer: a systematic review and pooled analysis. JAMA Oncol. 2017;3:1–6. doi: 10.1001/jamaoncol.2017.1516.
    1. Tomasello G, Petrelli F, Ghidini M, Russo A, Passalacqua R, Barni S. FOLFOXIRI plus bevacizumab as conversion therapy for patients with initially unresectable metastatic colorectal cancer: a systematic review and pooled analysis. JAMA Oncol. 2017;3:3–8. doi: 10.1001/jamaoncol.2017.1516.
    1. Karoui M, Penna C, Amin-Hashem M, Mitry E, Benoist S, Franc B, et al. Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg. 2006;243:1–7. doi: 10.1097/01.sla.0000193603.26265.c3.
    1. Ychou M, Rivoire M, Thezenas S, Guimbaud R, Ghiringhelli F, Mercier Blas A, et al. Induction chemotherapy (CT) with FOLFIRINOX or FOLFOX/FOLFIRI, plus cetuximab (CET) or bevacizumab (BEV) (by RAS status), in patients (pts) with primarily unresectable colorectal liver metastases (CRLM): results of the randomized UNICANCER PRODIGE 14-ACCO. J Clin Oncol. 2018;36:3535. doi: 10.1200/JCO.2018.36.15_suppl.3535.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj